Table 2.
One-Year Vein Graft Outcome Between Baseline HbA1c ≥6.5% and <6.5%
| 1-Year Outcome | HbA1c <6.5% | HbA1c ≥ 6.5% | HbA1c ≥6.5% vs. <6.5% Adjusted OR (95% CI) |
P Value |
|---|---|---|---|---|
| Per graft | n = 678 | n = 512 | ||
| FitzGibbon grade A | 584 (86.1) | 399 (77.9) | ||
| FitzGibbon grade B | 19 (2.8) | 19 (3.7) | ||
| FitzGibbon grade O | 75 (11.1) | 94 (18.4) | ||
| Patency (A) | 584 (86.1) | 399 (77.9) | 1.69 (1.08–2.64)a | 0.021 |
| Nonocclusion (A+B) | 603 (88.9) | 418 (81.6) | 1.70 (1.04–2.79)b | 0.034 |
| Per patient | n = 233 | n = 172 | ||
| FitzGibbon grade A | 177 (76.0) | 113 (65.7) | ||
| FitzGibbon grade B | 10 (4.3) | 13 (7.6) | ||
| FitzGibbon grade O | 46 (19.7) | 46 (26.7) | ||
| Patency (A) | 177 (76.0) | 113 (65.7) | 1.62 (1.01–2.60)a | 0.048 |
| Nonocclusion (A+B) | 187 (80.3) | 126 (73.3) | 1.41 (0.86–2.32)b | 0.174 |
Values are n (%) unless otherwise noted.
CI = confidence interval; HbA1c = glycated hemoglobin; OR = odds ratio, OR was adjusted for age, sex, medical history of hypertension and hyperlipidemia, SYNTAX score, target vessel distribution, antiplatelet therapy, and statin use at 1 year after coronary artery bypass graft; SYNTAX = Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery.
a
With nonpatency (B+O) as outcome.
b
With occlusion (O) as outcome.